4篇
您的检索式：作者名="Anna Signorile"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer显示文摘AIM: To identify suitable biomarkers of response to bevacizumab(BV)- it remains an open question. The measurement of serum vascular endothelial growth factor(VEGF) has been proposed as a predictive factor for this drug, even if literature data are contradictory. METHODS: We prospectively evaluated the role of BV, total and not BV-bound VEGF and angiopoietin-2(Ang-2) serum levels as potential predictive factors of response for BV in combination with an oxaliplatinbased chemotherapy. BV, Ang-2, total and not BVbound VEGF levels were measured at baseline, before 2^(nd) and 5^(th) cycle of oxaliplatin-based chemotherapy in 20 consecutive metastatic colorectal cancer patients. RESULTS: Results were correlated to response to treatment. Variability in BV levels have been found, with decreased level in less responding patients. In particular, the concentration of BV increased of 3.96 ± 0.69 folds in serum of responsive patients after 3 more cycles of therapy compared to those with stable or progressive disease with a 0.72 ± 0.25 and 2.10 ± 0.13 fold increase, respectively. The determination of free and total VEGF demonstrated that the ratio between the two values, evaluated immediately before the 2^(nd) and the 5^(th) cycle of therapy, decreased from 26.65% ± 1.33% to 15.50% ± 3.47% in responsive patients and from 53.41% ± 4.75 to 34.95% ± 2.88% in those with stable disease. Conversely, in those with progression of disease, the ratio showed the opposite behavior coming up from 25.99% ± 5.23% to 51.71% ± 5.28%. The Ang-2 levels did not show any relationship. CONCLUSION: Our data show that the ratio of not BV-bound VEGF to total VEGF serum and BV plasma concentrations for predicting the response to BV plus oxaliplatin-based chemotherapy could be a promising biomarker of response to BV. | Amalia Azzariti Letizia Porcelli Oronzo Brunetti Marzia Del Re Vito Longo Patrizia Nardulli Michele Signorile Jian-Ming Xu Angela Calabrese Anna Elisa Quatrale Evaristo Maiello Vito Lorusso Nicola Silvestris | 2016 | World Journal of Gastroenterology2016，22，27： | 4 |
| 2 | Mito- chondrial defect and PGC-let dysfimction in parkin-associated familial Parkinson's disease显示文摘 | Consiglia Pacelli Domenico De Rasmo Anna Signorile | 2011 | Biochimica et Biophysica Acta(BBA) - Molec- ular Basis of Disease2011，1812，8： | 1 |
| 3 | Mitochondrial defect and PGC-1α dysfunction in parkin -associated familial Parkinson’s disease显示文摘 | Consiglia Pacelli Domenico De Rasmo Anna Signorile Ignazio Grattagliano Giuseppe di Tullio Andria D’Orazio Beatrice Nico Giacomo Pietro Comi Dario Ronchi Ermanno Ferranini Domenico Pirolo Peter Seibel Susanna Schubert Antonio Gaballo Gaetano Villani Tizia | 2011 | BBA - Molecular Basis of Disease2011，，8： | 1 |
| 4 | Coinheritance of germline mutations in APC and MUTYH genes defines the clinical outcome of adenomatous polyposis syndromes显示文摘Familial adenomatous polyposis(FAP)and MUTYH-associ-ated polyposis(MAP)are colon cancer predisposition syn-dromes.FAP is an autosomal dominant inherited condition caused by germline mutations in the adenomatous polyposis coli(APC)gene and characterized by hundreds to thousands of colorectal adenomas. | Giovanna Forte Filomena Cariola Antonia Lucia Buonadonna Anna Filomena Guglielmi Andrea Manghisi Katia De Marco Valentina Grossi Candida Fasano Martina Lepore Signorile Paola Sanese Rosanna Bagnulo Nicoletta Resta b Vittoria Disciglio Cristiano Simone | 2023 | Genes & Diseases2023，10，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员